| Net profit of Aurobindo Pharma rose 1.97% to Rs 921.26 crore in the quarter ended March 2026 as against Rs 903.47 crore during the previous quarter ended March 2025. Sales rose 4.42% to Rs 8751.50 crore in the quarter ended March 2026 as against Rs 8381.12 crore during the previous quarter ended March 2025.
For the full year,net profit rose 0.54% to Rs 3504.75 crore in the year ended March 2026 as against Rs 3485.88 crore during the previous year ended March 2025. Sales rose 6.39% to Rs 33384.74 crore in the year ended March 2026 as against Rs 31378.13 crore during the previous year ended March 2025.
| Particulars | Quarter Ended | Year Ended | | Mar. 2026 | Mar. 2025 | % Var. | Mar. 2026 | Mar. 2025 | % Var. |
| Sales | 8751.50 | 8381.12 | 4 | 33384.74 | 31378.13 | 6 |
| OPM % | 20.00 | 21.00 | - | 20.51 | 20.88 | - |
| PBDT | 1769.18 | 1779.52 | -1 | 6955.37 | 6715.71 | 4 |
| PBT | 1290.61 | 1335.09 | -3 | 5177.18 | 5066.29 | 2 |
| NP | 921.26 | 903.47 | 2 | 3504.75 | 3485.88 | 1 |
|